SABCS 2022
Read the full Report (pdf)
San Antonio Breast Cancer Symposium
06–10 December 2022
San Antonio, TX, USA
Featured articles
CONTENTS
Online First
Early-Stage Breast Cancer
Anti-PD-1/anti-LAG-3 combination highly effective in HER2-negative breast cancer
MammaPrint test predictive for benefit of extended endocrine therapy
HR-positive/HER2-positive Breast Cancer: Trastuzumab-Deruxtecan
Trastuzumab deruxtecan effective in both second-line and neoadjuvant setting
HR-positive/HER2-negative Advanced Metastatic Breast Cancer
Benefit of adjuvant abemaciclib continues to deepen at longer follow-up
First-line ribociclib plus endocrine therapy outperforms combination chemotherapy
Treatment options beyond CDK4/6 inhibition
Triple-Negative Breast Cancer
Baseline CTC count can guide first-line treatment in HR-positive/HER-negative metastatic breast cancer
ZNF689 deficiency promotes intratumour heterogeneity and resistance to immune checkpoint blockade in TNBC
Oestradiol represses anti-tumoural immune response to promote progression of brain metastases
Basic and Translational Research
Resistance to CDK4/6 inhibitors is likely due to expansion of pre-existing resistant clones
Germline pathogenic variants for breast cancer also increase contralateral breast cancer risk
Low-dose tamoxifen still prevents recurrence from non-invasive breast cancer
Endocrine interruption to pursue pregnancy does not impact short-term disease in breast cancer
Miscellaneous
